CJC-1295: Long-Acting GHRH Analog Research

CJC-1295, a tetrasubstituted GHRH(1-29) analog with Drug Affinity Complex (DAC), provides sustained GH elevation in metabolic and body composition studies.

CJC-1295 Research Findings

Body composition improvements in obesity models by Sam Dagogo-Jack at the University of Tennessee showed 6% fat reduction over 12 weeks. Lipolysis enhancement per Jens Sandahl Christiansen at Aarhus University Hospital.

Muscle protein synthesis stimulation in sarcopenic models by Robert R. Wolfe at the University of Arkansas. Sleep quality enhancement alongside Ipamorelin by George Merriam at the University of Washington.

CJC-1295 Mechanisms

DAC technology extends half-life to 6-8 days via albumin binding. GHRH receptor agonism stimulates somatotroph GH release without desensitization.

CJC-1295 Research Horizons

Weekly dosing protocols by Theratechnologies Inc. Combination with secretagogues for enhanced pulsatility.

Links

• [Body Comp](https://pubmed.ncbi.nlm.nih.gov/16352683/)
• [Lipolysis](https://pubmed.ncbi.nlm.nih.gov/15033878/)